53 related articles for article (PubMed ID: 16570054)
1. Explaining the biological activity of transactivation-deficient p53 variants.
Tang M; Wahl GM; Nistér M
Nat Genet; 2006 Apr; 38(4):395-6; author reply 396-7. PubMed ID: 16570054
[No Abstract] [Full Text] [Related]
2. Simulated solar light-induced p53 mutagenesis in SKH-1 mouse skin: a dose-response assessment.
Verkler TL; Delongchamp RR; Miller BJ; Webb PJ; Howard PC; Parsons BL
Mol Carcinog; 2008 Aug; 47(8):599-607. PubMed ID: 18314877
[TBL] [Abstract][Full Text] [Related]
3. Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer.
Chien WP; Wong RH; Wu TC; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2009 Jul; 16(7):1918-24. PubMed ID: 19434453
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel, transactivation-defective splicing variant of p53 gene in patients with chronic lymphocytic leukemia.
Pekova S; Cmejla R; Smolej L; Kozak T; Spacek M; Prucha M
Leuk Res; 2008 Mar; 32(3):395-400. PubMed ID: 17688945
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional activation of cyclooxygenase-2 by tumor suppressor p53 requires nuclear factor-kappaB.
Benoit V; de Moraes E; Dar NA; Taranchon E; Bours V; Hautefeuille A; Tanière P; Chariot A; Scoazec JY; de Moura Gallo CV; Merville MP; Hainaut P
Oncogene; 2006 Sep; 25(42):5708-18. PubMed ID: 16682957
[TBL] [Abstract][Full Text] [Related]
6. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
7. Cooperative interactions of p53 mutation, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression.
Farazi PA; Glickman J; Horner J; Depinho RA
Cancer Res; 2006 May; 66(9):4766-73. PubMed ID: 16651430
[TBL] [Abstract][Full Text] [Related]
8. p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia.
Malisic E; Jankovic R; Majkic M; Dobricic J; Radulovic S
J BUON; 2008; 13(4):525-32. PubMed ID: 19145674
[TBL] [Abstract][Full Text] [Related]
9. p63 null mutation protects mouse oocytes from radio-induced apoptosis.
Livera G; Petre-Lazar B; Guerquin MJ; Trautmann E; Coffigny H; Habert R
Reproduction; 2008 Jan; 135(1):3-12. PubMed ID: 18159078
[TBL] [Abstract][Full Text] [Related]
10. p53 gene mutations in SKH-1 mouse tumors differentially induced by UVB and combined subcarcinogenic benzo[a]pyrene and UVA.
Wang Y; Zhou X; Weinstein E; Maryles B; Zhang Y; Moore J; Gao D; Atencio DP; Rosenstein BS; Lebwohl M; Chen HD; Xiao T; Wei H
Photochem Photobiol; 2008; 84(2):444-9. PubMed ID: 18248503
[TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway.
Zhang G; Chen F; Cao Y; See WA
Urol Oncol; 2007; 25(3):221-7. PubMed ID: 17483019
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis.
Raver-Shapira N; Marciano E; Meiri E; Spector Y; Rosenfeld N; Moskovits N; Bentwich Z; Oren M
Mol Cell; 2007 Jun; 26(5):731-43. PubMed ID: 17540598
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid carcinoma with anaplastic feature: association of a p53 gene mutation with anaplastic transformation.
Tamura G; Miyoshi H; Ogata SY; Sasou S; Kudoh S; Kikuchi J; Yanagawa N; Motoyama T
Pathol Int; 2009 Feb; 59(2):107-10. PubMed ID: 19154265
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia induces p53-dependent transactivation and Fas/CD95-dependent apoptosis.
Liu T; Laurell C; Selivanova G; Lundeberg J; Nilsson P; Wiman KG
Cell Death Differ; 2007 Mar; 14(3):411-21. PubMed ID: 16917513
[TBL] [Abstract][Full Text] [Related]
15. An unusual p53 mutation detected in Burkitt's lymphoma: 30 bp duplication.
Smardova J; Grochova D; Fabian P; Moulis M; Smarda J; Falkova I; Ravcukova B; Vankova J; Vasova I
Oncol Rep; 2008 Oct; 20(4):773-8. PubMed ID: 18813817
[TBL] [Abstract][Full Text] [Related]
16. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
17. Directed evolution of p53 variants with altered DNA-binding specificities by in vitro compartmentalization.
Fen CX; Coomber DW; Lane DP; Ghadessy FJ
J Mol Biol; 2007 Aug; 371(5):1238-48. PubMed ID: 17610896
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
19. Properties of the six isoforms of p63: p53-like regulation in response to genotoxic stress and cross talk with DeltaNp73.
Petitjean A; Ruptier C; Tribollet V; Hautefeuille A; Chardon F; Cavard C; Puisieux A; Hainaut P; Caron de Fromentel C
Carcinogenesis; 2008 Feb; 29(2):273-81. PubMed ID: 18048390
[TBL] [Abstract][Full Text] [Related]
20. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
